相关临床试验
1005
97 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1943
Unknown
4
0.4%
已完成
539
53.6%
Enrolling By Invitation
14
1.4%
尚未招募
41
4.1%
No Longer Available
3
0.3%
终止
108
10.8%
招募中
150
14.9%
暂停
2
0.2%
撤回
102
10.2%
进行中（未招募）
42
4.2%
暂无批准数据
- A matched-cohort study of 478 patients found PCSK9 inhibitor use was associated with a 31% lower risk of all-cause mortality compared to high-intensity statins alone (HR 0.69). - Two-year survival rates reached 62% in the PCSK9 inhibitor group versus 51% in the statin group, with median survival extending to approximately five years. - The survival benefit appeared independent of cardiovascular outcomes, suggesting a potential anticancer mechanism beyond cholesterol lowering. - Researchers emphasize that prospective randomized clinical trials are needed before changing clinical practice, with several trials already underway.
- ImPact Biotech reported that 66% of patients with unresectable locally advanced pancreatic ductal adenocarcinoma became eligible for surgery following treatment with Padeliporfin VTP at the lowest light dose in a Phase 1 trial. - The vascular targeted photodynamic therapy demonstrated a well-tolerated safety profile with no complications related to arterial injury, thrombosis, or other VTP-related morbidity in the initial cohort. - The company is pursuing strategic partnerships for its low-grade upper tract urothelial carcinoma program while advancing the pancreatic cancer indication, which represents a large market opportunity with potential for accelerated regulatory pathway. - Topline data from the Phase 3 ENLIGHTED trial in UTUC and NDA submission are expected in 2026, with additional LA-PDAC Phase 1 results anticipated throughout the year.
- The FDA has approved Awiqli (insulin icodec-abae), the first and only once-weekly basal insulin treatment for adults with type 2 diabetes, reducing injections from seven to one per week. - The approval is based on the ONWARDS phase 3a clinical program involving approximately 2,680 adults with uncontrolled type 2 diabetes, demonstrating efficacy in A1C reduction. - Awiqli offers an alternative to daily basal insulin injections and may improve patient adherence by providing a more manageable treatment routine. - The safety profile was consistent with daily basal insulin class, with common side effects including hypoglycemia, injection site reactions, and weight gain.
- Kamada has enrolled the first patient in the SHIELD trial, an investigator-initiated study evaluating CYTOGAM to prevent late cytomegalovirus infection in high-risk kidney transplant recipients. - The prospective, randomized, controlled multicenter study targets patients who are CMV seronegative with CMV seropositive donors, representing the highest risk group for late-onset CMV infection. - Up to one-third of kidney transplant patients may develop late CMV infection after stopping initial antiviral prophylaxis therapy, creating a significant unmet medical need. - The trial is led by recognized transplant infection experts Dr. Camille Kotton from Massachusetts General Hospital and Dr. David Wojciechowski from UT Southwestern Medical Center.
- CND Life Sciences received FDA Breakthrough Device Designation for its Syn-One Test, a skin biopsy diagnostic tool that demonstrates 95.5% sensitivity in detecting abnormal synuclein in patients with synuclein-associated diseases. - The company was awarded a $3 million NIH grant to conduct a three-year multicenter study investigating whether the Syn-One Test can predict Parkinson's disease risk in essential tremor patients. - A Yale University study showed the Syn-One Test changed diagnosis in 52% of cases and medical management in 60% of 149 evaluable patients, demonstrating significant clinical utility. - The diagnostic test uses proprietary immunofluorescence techniques to detect phosphorylated alpha-synuclein in cutaneous nerves through a simple in-office skin biopsy procedure.
- Circle Pharma's CID-078, a first-in-class oral cyclin A/B RxL inhibitor, demonstrated robust anti-tumor activity in preclinical models, including chemotherapy-resistant small cell lung cancer xenografts. - The research published in Nature reveals a dual mechanism where the inhibitor blocks cyclin A-E2F interactions causing DNA damage, then disrupts cyclin B-Myt1 interactions forcing damaged cells through division to trigger death. - The oral macrocycle therapy targets historically undruggable cyclins and shows particular promise for E2F-driven cancers including small cell lung cancer, triple-negative breast cancer, and tumors with RB1 alterations. - CID-078 is currently being evaluated in a Phase 1 clinical trial for patients with advanced solid tumors harboring RB1 alterations.
- Percheron Therapeutics released preclinical data published in Cancer Research showing HMBD-002 effectively blocked tumor growth in triple-negative breast cancer mouse models with statistically significant results (p < 0.0001). - The investigational drug targets VISTA immune checkpoint, which is expressed in 25-30% of TNBC tumors, addressing a significant unmet medical need affecting approximately 30,000 new US patients annually. - HMBD-002 demonstrates a potential dual mechanism of action, targeting both immune pathways and growth signals like EGFR, differentiating it from conventional immunotherapies such as pembrolizumab. - The company plans to advance HMBD-002 into phase II clinical trials with additional data expected in Q4 2025, following completion of ongoing phase I studies in advanced cancer patients.
- Signify Bio secured an oversubscribed $15 million initial financing round led by Actium Group with participation from Gates Foundation Strategic Investment Fund, Danaher Ventures, Eli Lilly, and American Cancer Society's BrightEdge. - The Dallas-based biotech company has developed three proprietary platforms including the SEND system for controlling protein secretion and localization, and iPhos lipid nanoparticles for targeted delivery. - The company aims to transform the human body into a biofactory for personalized protein therapeutics by combining signal peptide engineering with mRNA-encoded design capabilities. - Signify Bio maintains a strategic partnership with UT Southwestern Medical Center, providing access to scalable manufacturing and broad scientific expertise for advancing nucleic acid therapeutics.
- A retrospective study of 1,552 diabetic patients found that GLP-1 receptor agonist use after PCI for acute myocardial infarction reduced 3-year all-cause mortality by 26% compared to non-users. - The survival benefit occurred without corresponding improvements in in-stent restenosis or revascularization rates, suggesting broader cardiovascular protective effects beyond procedural outcomes. - Experts at the ASPC 2025 Congress emphasized that GLP-1s have become level 1a cardiovascular medications with FDA indications and guideline endorsements for cardiovascular protection. - Recent trials including SOUL and SURPASS demonstrated cardiovascular event reduction and mortality benefits, with some showing separation as early as 6 months after treatment initiation.
• Actinium Pharmaceuticals has enrolled the first patient in a pioneering trial evaluating Iomab-ACT as a targeted radiotherapy conditioning agent with commercial CAR-T therapy, with initial data expected in late 2025. • Iomab-ACT targets CD45 on immune cells and has shown promise in reducing serious CAR-T toxicities including ICANS and CRS, potentially addressing major barriers to CAR-T therapy access and efficacy. • The therapy could significantly expand the $4 billion CAR-T market by replacing conventional chemotherapy conditioning regimens, potentially benefiting approximately 150,000 patients diagnosed annually with eligible conditions.
